A Phase 4 interventional study of Dexamethasone 0.6 mg/kilogram body weight single dose and Placebo in Lower Respiratory Tract Infection (LRTI) and Recurrent Wheezing, sponsored by Norwegian University of Science and Technology. Not yet recruiting at 2 sites in 2 countries. Open to participants aged 3 Months to 24 Months. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Norwegian University of Science and Technology · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This trial investigates whether a single dose of dexamethasone will prevent recurrent wheezing in children at high-risk for asthma admitted to hospital with a lower respiratory tract infection (LRTI). Eligible children will be identified and enrolled upon hospital admission or during hospitalisation and allocated to receive either dexamethasone 0.6 mg/kilogram body weight or the similar number of placebo tablets (allocation ratio 1:1). The follow-up is 12 months and comprises scheduled on-site examinations by physician and study nurse, scheduled phone contacts, and registrations of new LRTI-episodes (if any). Nasopharyngeal swabs and blood will be collected at specified visits. The children will be invited to a follow-up study at school age for lung function assessments.
189 studies on the registry are indexed under Respiratory Sounds; 41 are open to participants now.
This study's planned enrollment of 486 is above the median of 120 across 98 interventional studies indexed under Respiratory Sounds.
Browse Respiratory Sounds studies →Norwegian University of Science and Technology is the lead sponsor of 495 studies on the registry; 47 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
LRTI (WHO definition LRTI: Cough or difficulties breathing
+ plus either fast breathing ( 2-12 months: > 50 breaths/minute 13-24 months: >40/minute) or: lower chest wall indrawing (retractions/nasal flare/difficulties breathing/wheeze) Acute:\<7 days duration of LRTI symptoms
+ 1 or more risk factors for recurrent wheeze:
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dexamethasone 0.6 mg/kilogram body weight single dose
Drug: Dexamethasone 0.6 mg/kilogram body weight single dose
Placebo single dose
Drug: Placebo
Drug page: DexamethasoneStudies of DexamethasoneDexamethasone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Dexamethasone 0.6 mg/kilogram body weight single dose
Placebo
New episode of wheeze within 12 months from inclusion, yes/no.
Whether or not the child had any new wheezing episode within the first 12 months. Wheeze is confirmed by doctor/study nurse or caregiver history supported by viedo. Any episode of wheeze is verified by TAL criteria scoring of 1 or more on the wheeze item (end-expiratory by stethoscope=1, Entire expiration (+/-audible without stethoscope)=2, inspiratory and expiratory (audible without stethoscope)=3). Full TAL scoring is assessed and included in episode evaluation.
Time frame: 12 months
Duration of symptoms for initial episode
Time frame: 6 weeks (4 - 8 weeks)
Number of episodes with breathing difficulty within 12 months
Episodes of breathing difficulty by 12 months follow-up, including: new breathing difficulty with wheeze (y/n), LRTI without wheeze (y/n), and any hospital admission for breathing difficulties (y/n).
Time frame: 12 months
Time to any episode with breathing difficulties within 12 months after inclusion.
Time in number of days.
Time frame: 12 months
Number of episodes with acute breathing difficulty (duration >24 hours) by 12 months.
Time frame: 12 months
Total number of days with breathing difficulty within 14 days of intervention.
Time frame: 14 days
Total number of days with breathing difficulty within 12 months
Time frame: 12 months
Lung function at 6 weeks (4 - 8 weeks) after inclusion
Tidal breathing flow-volume loop (TBFVL) and oscillometry at scheduled visit 6 (4 - 8) weeks after inclusion.
Time frame: 6 weeks
Lung function 12 months after inclusion
Tidal breathing flow-volume loop (TBFVL) and oscillometry at scheduled visit 12 months after inclusion.
Time frame: 12 months
Quality of Life 6 weeks (4 - 8 weeks) after inclusion.
Quality of Life assessment in children aged 3 - 24 months in Nepal only. Nepali verison of the Pediatric Quality of Life Inventory Infant Scales (PedsQL).
Time frame: 6 weeks
Quality of Life 12 months after inclusion
Quality of Life assessment in children aged 3 - 24 months in Nepal only. Nepali verison of the Pediatric Quality of Life Inventory Infant Scales (PedsQL).
Time frame: 12 months
Height development within 12 months of study entry
Height is measured in centimeters (cm) to the nearest 0.1cm, using a calibrated stadiometer for children \>24 months of age. For children \<24 months of age, lenght is measured in the recumbent position using an infantometer. Height is measured at inclusion, 6 weeks and 12 months after inclusion.
Time frame: 12 months
Body weight development within 12 months of study entry
Body weight in kilograms, 1 decimal. For children \>24 months of age, weight will be measured with light clothing using a calibrated electronic scale. For children \<24 months, weight will be measured without clothes or with a dry diaper only using a leveled pan scale. Body weight is measured at inclusion, 6 weeks and 12 months after inclusion.
Time frame: 12 months
Time to fulfill criteria for asthma, in accordance with GINA 2025 guidelines, within 12 months.
Criteria meeting GINA 2025 definitions for asthma in children \<=5 years of age: 1) symptom pattern consistent with asthma and not controlled; \>=3 episodes/year or symptoms most days or 2) symptoms occurring more than two days per week with a history of severe wheezing episodes AND: response to trial treatment.
Time frame: 12 months
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Feb 2027; primary completion for Jan 2029, 23 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone
Norwegian University of Science and Technology →